Literature DB >> 8863280

Effects of reducing sugars on the chemical stability of human relaxin in the lyophilized state.

S Li1, T W Patapoff, D Overcashier, C Hsu, T H Nguyen, R T Borchardt.   

Abstract

Sugars and polyols have been used routinely with lyophilized proteins and peptides as bulking agents, cryoprotectants, and lyoprotectants. However, reducing sugars may present a problem as excipients since they are potentially reactive with proteins. In this stability study of recombinant human relaxin (Rix) with various sugars as excipients in lyophilized formulations, we observed rapid covalent modifications of the protein in the presence of glucose. Analysis of the protein by LC/MS and tryptic mapping indicated two major degradation pathways. Covalent adducts of glucose with amino groups on the side chains of the protein (i.e., Lys and Arg) formed via the Maillard reaction. In addition, a significant amount of Ser cleavage from the C-terminal of the B-chain of relaxin was also identified when glucose was used as the excipient. It was observed that the latter reaction occurred to a greater extent in the solid state than in solution. We proposed a mechanism for this reaction involving an initial reaction of the Ser hydroxyl group with glucose followed by subsequent hydrolysis of the Trp-Ser amide bond via a cyclic intermediate. In contrast to glucose, mannitol (polyhydric alcohol) and trehalose (nonreducing sugar) produced stable, lyophilized formulations of Rix.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8863280     DOI: 10.1021/js950456s

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  13 in total

Review 1.  Impact of excipient interactions on solid dosage form stability.

Authors:  Ajit S Narang; Divyakant Desai; Sherif Badawy
Journal:  Pharm Res       Date:  2012-06-16       Impact factor: 4.200

Review 2.  Carrier-based strategies for targeting protein and peptide drugs to the lungs.

Authors:  Sally-Ann Cryan
Journal:  AAPS J       Date:  2005-03-24       Impact factor: 4.009

3.  Biophysical and formulation studies of the Schistosoma mansoni TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis.

Authors:  Weiqiang Cheng; Elena Curti; Wanderson C Rezende; Clifford Kwityn; Bin Zhan; Portia Gillespie; Jordan Plieskatt; Sangeeta B Joshi; David B Volkin; Peter J Hotez; C Russell Middaugh; Maria Elena Bottazzi
Journal:  Hum Vaccin Immunother       Date:  2013-07-23       Impact factor: 3.452

4.  Photolytic labeling to probe molecular interactions in lyophilized powders.

Authors:  Lavanya K Iyer; Balakrishnan S Moorthy; Elizabeth M Topp
Journal:  Mol Pharm       Date:  2013-10-29       Impact factor: 4.939

Review 5.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

6.  Membrane Stability during Biopreservation of Blood Cells.

Authors:  Christoph Stoll; Willem F Wolkers
Journal:  Transfus Med Hemother       Date:  2011-03-21       Impact factor: 3.747

Review 7.  The Principles of Freeze-Drying and Application of Analytical Technologies.

Authors:  Kevin R Ward; Paul Matejtschuk
Journal:  Methods Mol Biol       Date:  2021

Review 8.  Photo-Degradation of Therapeutic Proteins: Mechanistic Aspects.

Authors:  Christian Schöneich
Journal:  Pharm Res       Date:  2020-02-03       Impact factor: 4.200

Review 9.  A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease.

Authors:  Qibin Zhang; Jennifer M Ames; Richard D Smith; John W Baynes; Thomas O Metz
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

10.  Isothermal vitrification methodology development for non-cryogenic storage of archival human sera.

Authors:  Rebekah Less; Kristin L M Boylan; Amy P N Skubitz; Alptekin Aksan
Journal:  Cryobiology       Date:  2013-01-24       Impact factor: 2.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.